Navigation Links
Minnesota partnership advances potential MS therapy
Date:4/17/2008

ROCHESTER/MINNEAPOLIS, Minn. A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy a medication for multiple sclerosis to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.

The antibody known as rHIgM22, developed at Mayo Clinic, was produced and purified in the Biotherapeutic Protein Production Laboratory created by a Partnership infrastructure award in 2006. This laboratory was developed within the Molecular and Cellular Therapeutics Facility on the St. Paul campus of the University of Minnesota. The therapy is under license to Acorda Therapeutics, Inc. (NASDAQ: ACOR), which is supporting the development of this potential therapy. This includes the Minnesota Partnerships transfer of remaining production and purification to Biovest, Inc., in Minneapolis.

The preclinical success and the promise of this program to date have only enhanced our commitment to the continued advancement of this potential new therapy for people with multiple sclerosis, says Ron Cohen, M.D., Acorda president and CEO. The Partnership has provided a mechanism for academic and commercial institutions to work together effectively in the early stages of developing a promising and innovative therapeutic approach to a very challenging condition.

The importance of the antibody as a promoter of myelin repair (remyelination) was recognized in studies using experimental animal models of multiple sclerosis. The studies were directed by Moses Rodriguez, M.D., a Mayo Clinic neurologist. Multiple sclerosis is a progressive disease, caused by damage to the myelin sheath that surrounds nerves. It can affect the brain and the spinal cord, leaving patients permanently disabled. The rHIgM22 antibody initiates the re-growth or repair of the damaged myelin sheath but has yet to be tested in patients.

The initial synthetic production of the therapeutic antibody was developed in the laboratory of Larry Pease, Ph.D., chair of immunology at Mayo. Early stage process development was also performed in collaboration with Acorda Therapeutics. The Partnership facility subsequently developed production of the antibody into a validated process that can be used to produce antibody for patient studies. John Wagner, M.D., at the University of Minnesota, and Dr. Pease were the principal investigators on the Minnesota Partnership grant. The grant established the protein production facility with the mission of providing good manufacturing (GMP) technical support to investigators at the University of Minnesota and Mayo Clinic to move laboratory advancements into clinical trials. The developmental work on this antibody at the protein production facility was funded by philanthropic gifts from the Eugene Applebaum Family Foundation, the Conrad N. Hilton Foundation, and anonymous benefactors.

The Minnesota Partnership was instrumental in providing the infrastructure to develop this monoclonal antibody to this point, says Dr. Pease. This antibody would not be headed into clinical studies or toward commercialization otherwise.

This is exactly what the Partnership is intended to do, says program director Eric Wieben, Ph.D. That is to promote interactions between the two leading medical research institutions in Minnesota and to accelerate medical discoveries that can be commercialized for the benefit of patients while improving our states economy.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Securians Minnesota Life Continues to Climb Group Life Rankings
2. Fresh Air Campaign to Showcase Minnesotans Love of Smoke-Free Air
3. Four Minnesota Hospitals Rate High For Patient Safety and Quality
4. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
5. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
6. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
7. New National Medicaid Study: Minnesota Under Funds Seniors Nursing Home Care $167 Million Annually
8. Blue Cross and Partners to Host Combat Stress Conference for Minnesotas Health Care Professionals
9. TV Documentary Examines Three Decades of Tobacco Politics, Policies and People in Minnesota
10. Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesotas Statewide, Smoke-Free Law
11. Mayo Clinic Calls for Thorough Review of Canadian Pacifics Acquisition of the Dakota, Minnesota & Eastern Railroad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: